Granted Patent
B2
US 12,576,074 · App. 18/186,668 · Granted Mar 17, 2026
Kits and methods for induction of cardioversion in subjects with atrial arrhythmias
Inventors:
Luiz Belardinelli (Palo Alto, CA); Carlos Schuler (Kensington, CA); Miguel Guzman (San Jose, CA)
Assignee:
InCarda Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are methods and kits for treating or preventing a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia, using potassium channel inhibitors and class I antiarrhythmic agents. Also disclosed herein are methods and kits for treating a heart condition via an intravenously, orally, or inhalationally administered fixed-dose combination of a sodium channel blocker and a class I antiarrhythmic agent.
Claims (26)
1 . A method of treating a subject suffering from atrial arrhythmia, comprising intravenously administering to said subject a pharmaceutical composition, wherein the pharmaceutical composition comprises
a sodium channel blocker that is flecainide or a pharmaceutically acceptable salt thereof; and
a potassium channel blocker selected from the group consisting of: ibutilide or a pharmaceutically acceptable salt thereof, and dofetilide or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein said sodium channel blocker is flecainide acetate.
3 . The method of claim 1 , wherein said sodium channel blocker is flecainide hydrochloride.
4 . The method of claim 2 , wherein said administering comprises administering flecainide acetate in an amount that is about 0.1 mg to about 2 mg per kilogram of said subject.
5 . The method of claim 2 , wherein said administering comprises administering flecainide acetate in an amount that is about 1 mg per kilogram of said subject.
6 . The method of claim 2 , wherein said administering comprises administering flecainide acetate in an amount that is about 5 mg to about 300 mg.
7 . The method of claim 1 , wherein said potassium channel blocker is ibutilide or a pharmaceutically acceptable salt thereof.
8 . The method of claim 1 , wherein said potassium channel blocker is ibutilide hemifumarate.
9 . The method of claim 8 , wherein said administering comprises administering ibutilide hemifumarate in an amount that is about 0.001 mg to about 0.25 mg per kilogram of said subject.
10 . The method of claim 8 , wherein said administering comprises administering ibutilide hemifumarate in an amount that is about 0.007 mg per kilogram of said subject.
11 . The method of claim 8 , wherein said administering comprises administering ibutilide hemifumarate in an amount that is about 0.01 mg to about 15 mg.
12 . The method of claim 1 , wherein said pharmaceutical composition is in liquid unit dosage form.
13 . The method of claim 7 , wherein a mass/mass ratio of said flecainide or pharmaceutically acceptable salt thereof to said ibutilide or pharmaceutically acceptable salt thereof is from 60:1 to 240:1.
14 . The method of claim 7 , wherein a mass/mass ratio of said flecainide or pharmaceutically acceptable salt thereof to said ibutilide or pharmaceutically acceptable salt thereof is about 120:1.
15 . The method of claim 12 , wherein said pharmaceutical composition comprises from about 1 mg/mL to about 10 mg/mL flecainide or pharmaceutically acceptable salt thereof.
16 . The method of claim 12 , wherein said pharmaceutical composition comprises about 0.001 mg/mL to about 1 mg/mL ibutilide or pharmaceutically acceptable salt thereof.
17 . The method of claim 1 , wherein said atrial arrhythmia is selected from the group consisting of: supraventricular tachycardia, paroxysmal supraventricular tachycardia, atrial fibrillation, paroxysmal atrial fibrillation, persistent and permanent atrial fibrillation, atrial flutter, paroxysmal atrial flutter, and lone atrial fibrillation.
18 . The method of claim 1 , wherein said atrial arrhythmia comprises paroxysmal atrial fibrillation.
19 . The method of claim 1 , wherein said atrial arrhythmia comprises persistent atrial fibrillation.
20 . The method of claim 1 , wherein said potassium channel blocker is dofetilide or a pharmaceutically acceptable salt thereof.
21 . The method of claim 20 , wherein said administering comprises administering dofetilide in an amount that is about 1 μg to about 5 μg per kilogram of said subject.
22 . The method of claim 20 , wherein said administering comprises administering dofetilide in an amount that is about 0.002 mg to about 2 mg.
23 . The method of claim 20 , wherein a mass/mass ratio of said flecainide or pharmaceutically acceptable salt thereof to said dofetilide or pharmaceutically acceptable salt thereof is from 60:1 to 480:1.
24 . The method of claim 20 , wherein said pharmaceutical composition comprises about 1 μg/mL to about 40 μg/mL dofetilide or pharmaceutically acceptable salt thereof.
Assignments (3)
SECURITY INTEREST
Recorded Mar 13, 2025
From: INCARDA THERAPEUTICS, INC.
To: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT
Reel/Frame 070515/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 2, 2024
From: BELARDINELLI, LUIZ; SCHULER, CARLOS; GUZMAN, MIGUEL
To: INCARDA THERAPEUTICS, INC.
Reel/Frame 066978/0853 →
SECURITY INTEREST
Recorded Dec 27, 2023
From: INCARDA THERAPEUTICS, INC.
To: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT
Reel/Frame 065963/0977 →
Continuity (5)
Continuation
PCTUS2021064213
· Dec 17, 2021
Provisional Application
63153492
· Feb 25, 2021
Provisional Application
63127089
· Dec 17, 2020
References Cited (121)
US 7951137B2
· Mehra et al.
· 2011
[cited by applicant]
US 8106099B2
· Brendel et al.
· 2012
[cited by applicant]
US 8974828B2
· Schuler et al.
· 2015
[cited by applicant]
US 9597302B1
· Yan et al.
· 2017
[cited by applicant]
US 20020161018A1
· Smith et al.
· 2002
[cited by applicant]
US 20060062739A1
· Hofmann et al.
· 2006
[cited by applicant]
US 20100183725A1
· Mohsen et al.
· 2010
[cited by applicant]
US 20150045305A1
· Belardinelli et al.
· 2015
[cited by applicant]
US 20190060230A1
· Schuler et al.
· 2019
[cited by applicant]
US 20210228825A1
· Narasimhan et al.
· 2021
[cited by applicant]
EP 2861254B1
· 2020
[cited by applicant]
WO WO2010107964A1
· 2010
[cited by applicant]
WO WO2013112932A1
· 2013
[cited by applicant]
WO WO2017136421A1
· 2017
[cited by applicant]
WO WO2018209107A1
· 2018
[cited by applicant]
WO WO2019183470A2
· 2019
[cited by applicant]
WO WO2019236694A1
· 2019
[cited by applicant]
WO WO2021022058A2
· 2021
[cited by applicant]
Tikosyn (dofetilide) Capsules Drug Label (Pfizer Labs, Revised Jan. 2014, 30 pages) (Year: 2014).
[cited by examiner]
Betapace (sotalol hydrochloride) Tablets Drug Label (Covis Pharma, Revised May 2016, 22 pages) (Year: 2016).
[cited by examiner]
Flecainide Acetate Tablets Drug Label (County Line Pharmaceuticals, LLC, Sep. 2016, 6 pages) (Year: 2016).
[cited by examiner]
Corvert (Ibutilide fumarate injection) Drug Label (Pharmacia & Upjohn, Revised Oct. 2000, 6 pages) (Year: 2000).
[cited by examiner]
Narayan et al. J. Interv. Card. Electrophysiol., 2006, vol. 15, p. 175-178 (Year: 2006).
[cited by examiner]
Part 6: Advanced Cardiovascular Life Support Section 5: Pharmacology I: Agents for Arrhythmias. Resuscitation. 46(1):135-153 (2017).
[cited by applicant]
European Application No. 21907959.7 European Search Report dated Oct. 10, 2024.
[cited by applicant]
Belardinelli et al., A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther. Jan. 2013;344(1):23-32. doi: 10.1124/jpet. 112.198887. Epub Sep. 25…
[cited by applicant]
Chan et al., Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram, QJM: An International Journal of Medicine, vol. 100, Issue 10, Oct. 2007, pp. 609-615.
[cited by applicant]
Chiladakis et al., Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter. J Am Coll Cardiol. Aug. 18, 2004;44(4):859-63.
[cited by applicant]
Fenrich et al. Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy. J Am Coll Cardiol. Apr. 1995;25(5):1195-8.
[cited by applicant]
Hongo et al., Use of Ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. J Am Coll Cardiol. Aug. 18, 2004;44(4):864-8.
[cited by applicant]
International Search Report and Written Opinion issued in PCT/US2021064213 on May 4, 2022.
[cited by applicant]
Johannesen et al., Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial. Clin Pharmacol Ther. Feb. 2016;99(2):214-23.
[cited by applicant]
Korantzopoulos et al., Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation. Heart (British Cardiac Society). 92. 631-4 (2006).
[cited by applicant]
Li Y, et al. Pharmacokinetic and pharmacodynamic properties of a single intravenous dose of ibutilide fumarate: a phase I, randomized, open-label, increasing-dose study in healthy Chinese men. Clin Ther. Sep. 2007;29(9)…
[cited by applicant]
Liu et al., Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation. Journal of the American Heart Association. 6. 10.1161/JAHA.117.005482, May 2017.
[cited by applicant]
Reiffel et al., The actions of ibutilide and class Ic drugs on the slow sodium channel: new insights regarding individual pharmacologic effects elucidated through combination therapies. J Cardiovasc Pharmacol Ther. Jul.…
[cited by applicant]
Sahu et al., Ibutilide is Safe for Cardioversion of Atrial Fibrillation in Patents on Concomitant Antiarrhythmic Agents (Abstract). PACE 42:743, 1999.
[cited by applicant]
Themistoclakis et al., Class IC Drug Plus Ibutilide for Acute Cardioversion of Atrial Fibrillation: What is the Rationale and What are the Results?. 10.1007/978-88-470-2103-7_59 (2002).
[cited by applicant]
U.S. Appl. No. 17/708,732 Notice of Allowance dated May 8, 2024.
[cited by applicant]
Wang T, et al. The development and testing of intravenous dosing regimens: application to flecainide for the suppression of ventricular arrhythmias. Clin Pharmacol Ther. May 1988;43(5):499-508. Erratum in: Clin Pharmaco…
[cited by applicant]
Burashnikov, Alexander, and Charles Antzelevitch. New developments in atrial antiarrhythmic drug therapy. Nature Reviews Cardiology 7(3):139-148 (2010).
[cited by applicant]
Burashnikov, Alexander et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazin…
[cited by applicant]
Burashnikov, Alexander et al. Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation. Heart Rhythm 12(4):836-844 (2015).
[cited by applicant]
Burashnikov, Alexander et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. Journal of the American College of Cardiology 56(15):1216-1224 (2010).
[cited by applicant]
Coumel, Philippe et al. Logic and Empiricism in the Selection of Antiarrhythmic Agents: The Role of Drug Combinations. Drugs 29(Suppl_4):68-76 (1985).
[cited by applicant]
El-Bizri, Nesrine et al. Eleclazine exhibits enhanced selectivity for long QT syndrome type 3-associated late Na+ current. Heart Rhythm 15(2):277-286 (2018).
[cited by applicant]
Fuster, Valentin et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundat…
[cited by applicant]
Kornyeyev, Dmytro et al. Contribution of the late sodium current to intracellular sodium and calcium overload in rabbit ventricular myocytes treated by anemone toxin. American Journal of Physiology-Heart and Circulatory…
[cited by applicant]
Lee, Kai S. et al. Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. European journal of pharmacology 234(1):43-53 (1993).
[cited by applicant]
Liu, Tengxian et al. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart rhythm 3(8):948-956 (2006).
[cited by applicant]
Mirams, Gary R. et al. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovascular research 91(1):53-61 (2011).
[cited by applicant]
Ni, Haibo et al. Populations of in silico myocytes and tissues reveal synergy of multiatrial-predominant K+-current block in atrial fibrillation. British journal of pharmacology 177(19):4497-4515 (2020).
[cited by applicant]
Ni, Haibo. et al. Synergistic Anti-arrhythmic effects in human atria with combined use of sodium blockers and acacetin. Frontiers in Physiology 8:946, 1-21 (2017).
[cited by applicant]
Oral, Hakan et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. New England Journal of Medicine 340(24):1849-1854 (1999).
[cited by applicant]
Reiffel, James A. et al. The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circulation: Arrhythmia and Electrophysiology 8…
[cited by applicant]
Sun, Xue-Rong et al. Low-dose ibutilide combined with catheter ablation of persistent atrial fibrillation: procedural impact and clinical outcome. Cardiology research and practice 2019(1):3210803, 1-10 (2019).
[cited by applicant]
Anno, Takafumi, and Luc M. Hondeghem. Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery. Circulation research 66(3):789-803 (19…
[cited by applicant]
Antzelevitch, Charles, and Luiz Belardinelli. The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. Journal of Cardiovascular Electrophysiology 17(Suppl 1):S79-S8…
[cited by applicant]
Belardinelli, Luiz. et al. Cardiac late Na(+) current: proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress. Heart Rhythm 12(2):440-448 (2015).
[cited by applicant]
Breindahl, Torben. Therapeutic drug monitoring of flecainide in serum using high-performance liquid chromatography and electrospray mass spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications 74…
[cited by applicant]
Burashnikov, Alexander. et al. Effect of flecainide and ibutilide alone and in combination to terminate and prevent recurrence of atrial fibrillation. Circulation: Arrhythmia and Electrophysiology 17(1):e012454, 24-33 (…
[cited by applicant]
Burashnikov, Alexander. Late INa inhibition as an antiarrhythmic strategy. Journal of Cardiovascular Pharmacology 70(3):159-167 (2017).
[cited by applicant]
Cogolludo, Angel L. et al. Antagonism by class I antiarrhythmic drugs of levcromakalim-induced relaxation in isolated rat aorta. The Journal of Pharmacology and Experimental Therapeutics 287(1):81-86 (1998).
[cited by applicant]
Cohen, Alberto A. et al. Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction. American Heart Journal 110(6):1193-1196 (1985).
[cited by applicant]
Conard, G. J. et al. Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans. Clinical Therapeutics 6(5):643-652 (1984).
[cited by applicant]
Conard, Gordon J., and Robert E. Ober. Metabolism of flecainide. The American Journal of Cardiology 53(5):41B-51B (1984).
[cited by applicant]
Deneer, V. H. M. et al. Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation. European Journal of Clinical Pharmacology 60(10):693…
[cited by applicant]
Echt, Debra S., and Jeremy N. Ruskin. Use of flecainide for the treatment of atrial fibrillation. The American Journal of Cardiology 125(7):1123-1133 (2020).
[cited by applicant]
Falk, Rodney H. et al. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Journal of the American College of Cardiology 29(2):385-390 (1997).
[cited by applicant]
Follmer, C. H., and T. J. Colatsky. Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Circulation 82(1):289-293 (1990).
[cited by applicant]
Gossinger, Heinz David. et al. Combined sotalol and flecainide given at low dosage in patients with the Wolff-Parkinson-White syndrome. International journal of cardiology 26(3):380-382 (1990).
[cited by applicant]
Hilliard, Fredrick A. et al. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. Journal of Molecular and Cellular Cardiology 4…
[cited by applicant]
Hoffmeister, H. M. et al. Negative inotropic effect of class-I-antiarrhythmic drugs: comparison of flecainide with disopyramide and quinidine. European Heart Journal 8(10):1126-1132 (1987).
[cited by applicant]
Jackson, N. et al. Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation. Clinical Pharmacology & Therapeutics 37(6):619-624 (1985).
[cited by applicant]
James, M. A. et al. Combined anti-arrhythmic therapy with class 1 and class 3 drugs. Postgraduate Medical Journal 65(766):519-524 (1989).
[cited by applicant]
Johannesen, Lars. et al. Late sodium current block for drug-induced long QT syndrome: results from a prospective clinical trial. Clinical Pharmacology & Therapeutics 99(2):214-223 (2016). Published Online Nov. 28, 2015.
[cited by applicant]
Josephson, Martin A. et al. Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. American Heart Journal 109(1):41-45 (1985).
[cited by applicant]
Kihara, Yasuki. et al. Mechanisms of negative inotropic effects of class Ic antiarrhythmic agents: comparative study of the effects of flecainide and pilsicainide on intracellular calcium handling in dog ventricular myo…
[cited by applicant]
Kowey, Peter R. et al. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter. The American Journal of Cardiology 78(8):46-52 (1996).
[cited by applicant]
Lee, Kai S., and Esther W. Lee. Ionic mechanism of ibutilide in human atrium: evidence for a drug-induced Na+ current through a nifedipine-inhibited inward channel. The Journal of Pharmacology and Experimental Therapeut…
[cited by applicant]
Legrand, Victor. et al. Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy. European Heart Journal 6(8):664-671 (1985).
[cited by applicant]
Legrand, Victor. et al. Hemodynamic effects of a new antiarrhythmic agent, flecainide (R-818), in coronary heart disease. The American Journal of Cardiology 51(3):422-426 (1983).
[cited by applicant]
Li, Yishi. et al. Pharmacokinetic and pharmacodynamic properties of a single intravenous dose of ibutilide fumarate: a phase I, randomized, open-label, increasing-dose study in healthy Chinese men. Clinical Therapeutics…
[cited by applicant]
Lynch Jr, Joseph J. et al. Comparison of binding to rapidly activating delayed rectifier K+ channel, IKr, and effects on myocardial refractoriness for class III antiarrhythmic agents. Journal of cardiovascular pharmacol…
[cited by applicant]
Lynch Jr, Joseph J et al. Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues. Journal of Cardiovascular …
[cited by applicant]
Marum, Alexandre A. et al. Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administratio…
[cited by applicant]
Muhiddin, Khulood A. et al. Effect of flecainide on cardiac output. Clinical Pharmacology and Therapeutics 37(3):260-263 (1985).
[cited by applicant]
Perez-Vizcaino, Francisco. et al. Effects of flecainide on isolated vascular smooth muscles of rat. British Journal of Pharmacology 104(3):726-730 (1991).
[cited by applicant]
Perry, Matthew. et al. Structural determinants of HERG channel block by clofilium and ibutilide. Molecular Pharmacology 66(2):240-249 (2004).
[cited by applicant]
Pham, Thai V. et al. Testosterone diminishes the proarrhythmic effects of dofetilide in normal female rabbits. Circulation 106(16):2132-2136 (2002).
[cited by applicant]
Price, Jack F. et al. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children 1 year of age. Journal of the American College of Cardiology 39(3):517-520 (2002).
[cited by applicant]
Reiffel, James A. and Mark Blitzer. The actions of ibutilide and class Ic drugs on the slow sodium channel: new insights regarding individual pharmacologic effects elucidated through combination therapies. Journal of Ca…
[cited by applicant]
Rythmol(propafenone hydrochloride tablets). Product Label Information. Reference ID: 4344605 (pp. 1-24) (Approval 1989/Revised 2018).
[cited by applicant]
Santinelli, Vincenzo. et al. Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function. Chest 103(4):1068-1073 (1993).
[cited by applicant]
Scamps, F. et al. Inhibition of ICa in single frog cardiac cells by quinidine, flecainide, ethmozin, and ethacizin. American Journal of Physiology-Cell Physiology 256(3):C549-C559 (1989).
[cited by applicant]
Schulze, J. J. and J Knops. Effects of flecainide on contractile force and electrophysiological parameters in cardiac muscle. Arzneimittel-Forschung 32(9):1025-1029 (1982).
[cited by applicant]
Serruys, P. W. et al. The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease. British Journal of Clinical Pharmacology 16(1):51-59 (1983).
[cited by applicant]
Stambler, Bruce S. et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 94(7):1613-1621 (1996).
[cited by applicant]
Tisdale, James E. et al. Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction. The Journal of Clinical Pharmacology 52(9):1296-1305 (20…
[cited by applicant]
Tisdale, James E. et al. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction. Pharmacotherapy 28(12):1461-1470 (2008).
[cited by applicant]
Tjandra-Maga, Tikma Budya et al. Flecainide: single and multiple oral dose kinetics, absolute bioavailability and effect of food and antacid in man. British Journal of Clinical Pharmacology 22(3):309-316 (1986).
[cited by applicant]
Van Midendorp, Lars B. et al. Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts. Europace 16(8):1249-1256 (2014).
[cited by applicant]
Verdouw, Pieter D. et al. Antiarrhythmic and hemodynamic actions of flecainide acetate (R-818) in the ischemic porcine heart. Journal of Cardiovascular Pharmacology 1(4):473-486 (1979).
[cited by applicant]
Vicente, Jose. et al. Electrocardiogramarkers for detection of drug-induced late sodium current block. Plos One 11(12):e0163619, 1-16 (2016).
[cited by applicant]
Vicente, Jose. et al. Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the “CiPA” initiative and design of a prospective clinical validation study. Clinical Pharmacology and Therapeutics 103(…
[cited by applicant]
Yang, Tao. et al. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effe…
[cited by applicant]